Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >
Companies Commented On
- Anthera Pharmaceuticals Inc.
- BIND Therapeutics Inc.
- Celgene Corp.
- Celldex Therapeutics Inc.
- Cerus Corp.
- Compugen Ltd.
- CytoSorbents Corp.
- Incyte Corp.
- Novavax Inc.
- Omeros Corp.
- OncoGenex Pharmaceuticals Inc.
- Pharmacyclics Inc.
- Pluristem Therapeutics Inc.
- Prana Biotechnology Ltd.
- Threshold Pharmaceuticals Inc.
- Verastem Inc.
Dr. George Zavoico joined H.C. Wainwright & Co. in January 2014 to focus on healthcare research. He has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector. Before joining HCW, Zavoico was managing director and senior equity analyst at MLV & Co., and helped establish the healthcare equity research platform there. Previously, Zavoico was an equity research analyst in the healthcare sector at Westport Capital Markets and Cantor Fitzgerald. Prior to working as an analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters.
Shining a Light on Overlooked and Underfollowed Biotechs: George Zavoico (3/6/14) Prospecting for hidden biotech gems makes sense, says H.C. Wainwright & Co. Managing Director George Zavoico, who recently joined the firm's healthcare equity research team. The digging can be hard, but the rewards of successful diligence are huge. In this interview with The Life Sciences Report, Zavoico takes readers on a discovery tour that follows clinical trial data to new ideas that could bring windfalls to portfolios down the road.
Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (1/15/14) 2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.
Still Time to Catch Big Growth in Biotech: George Zavoico (8/15/13) Biotech has had a scorching run for more than a year and a half, but as broader markets approach more realistic valuations with less potential upside, it becomes even more important to be invested in the right companies with truly meaningful catalysts on the horizon. George Zavoico of MLV & Co. knows how to pick winners from the field, and offers up solid ideas with visible growth drivers in this interview with The Life Sciences Report. Your inner gambler should take note: A beaten-down micro- or small-cap company might, with a bit of luck, bring home the gold.
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
"The combination of DMPI's VAL-083 and radiation therapy showed an immediate survival benefit in glioblastoma multiforme." (10/30/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Brandon Primack More >